Amendment: SEC Form SCHEDULE 13G/A filed by HOOKIPA Pharma Inc.

$HOOK
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $HOOK alert in real time by email





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  Percentage calculated based on 9,655,022 shares of Common Stock outstanding on November 11, 2024, as reported in the Form 10-Q filed by the Issuer for the quarter ended September 30, 2024.


SCHEDULE 13G




Comment for Type of Reporting Person:  Percentage calculated based on 9,655,022 shares of Common Stock outstanding on November 11, 2024, as reported in the Form 10-Q filed by the Issuer for the quarter ended September 30, 2024.


SCHEDULE 13G




Comment for Type of Reporting Person:  Percentage calculated based on 9,655,022 shares of Common Stock outstanding on November 11, 2024, as reported in the Form 10-Q filed by the Issuer for the quarter ended September 30, 2024.


SCHEDULE 13G



 
EcoR1 Capital, LLC
 
Signature:/s/ Oleg Nodelman
Name/Title:Manager
Date:02/14/2025
 
Oleg Nodelman
 
Signature:/s/ Oleg Nodelman
Name/Title:Reporting person
Date:02/14/2025
 
EcoR1 Capital Fund Qualified, L.P.
 
Signature:/s/ Oleg Nodelman
Name/Title:Manager of the General Partner, EcoR1 Capital, LLC
Date:02/14/2025
Get the next $HOOK alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HOOK

DatePrice TargetRatingAnalyst
12/20/2024$48.00 → $2.00Outperform → Sector Perform
RBC Capital Mkts
11/15/2024$50.00 → $48.00Outperform
RBC Capital Mkts
12/2/2022Neutral → Underperform
BofA Securities
2/17/2022$15.00 → $8.00Buy
HC Wainwright & Co.
2/16/2022$3.00 → $4.00Outperform
SVB Leerink
11/12/2021$6.00Overweight → Equal-Weight
Morgan Stanley
11/11/2021$21.00 → $15.00Buy
HC Wainwright & Co.
11/10/2021$28.00 → $10.00Outperform
SVB Leerink
More analyst ratings

$HOOK
Press Releases

Fastest customizable press release news feed in the world

See more
  • HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV

    HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HIV) Under the collaboration agreement, HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial Primary completion expected H2 2025 NEW YORK and VIENNA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that enrollment is complete in th

    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

    NEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious disease, today announced a notice to shareholders regarding U.K. disclosure requirements. HOOKIPA directs the attention of its shareholders to certain disclosure requirements applicable to the potential all-share acquisition by HOOKIPA of Poolbeg Pharma plc, which was announced on January 2, 2025. HOOKIPA's shares are admitted to trading on the NASDAQ Capital Market exchange. The relevant disclosure requirements are set out in

    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates

    Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data First patients dosed in Phase 2 investigator led study with MSKCC in new clinical setting as adjuvant therapy for head and neck cancer Strength of HB-700 KRAS-inhibitor program highlighted by preclinical dataset presented at recent RAS Targeted Drug Development Summit NEW YORK and VIENNA, Austria, Nov. 14, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")

    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

$HOOK
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$HOOK
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$HOOK
SEC Filings

See more

$HOOK
Leadership Updates

Live Leadership Updates

See more
  • HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates

    Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data First patients dosed in Phase 2 investigator led study with MSKCC in new clinical setting as adjuvant therapy for head and neck cancer Strength of HB-700 KRAS-inhibitor program highlighted by preclinical dataset presented at recent RAS Targeted Drug Development Summit NEW YORK and VIENNA, Austria, Nov. 14, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")

    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • HOOKIPA Pharma Announces Board of Directors Changes

    NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Director Julie O'Neill as Non-Executive Chair of the Company's Board of Directors. She succeeds Jan van de Winkel, who has decided to step down from the Board effective August 30, 2024, due to increasing time commitments from his executive position as Chief Executive Officer of Genmab A/S. The Company also announced that Tim Reilly has chosen to step down from the Board, also effective August 30th, to be able to dedicate more time to his o

    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

    New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 "AVALON-1" study with eseba-vec in Q4 2024 ASCO 2024 Presentation:   Reported best-in-class Phase 2 data for first-line HPV16+ head and neck cancer patients treated with eseba-vec (formerly HB-200) in combination with pembrolizumab during oral presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual MeetingRegulatory Progress:   Announced alignment with U.S. Food and Drug Administration (FDA) for the AVALON-1 Phase 2/3 pivotal trial design and protocol for eseba-vec, in combination with pembrolizumab for the first-li

    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

$HOOK
Financials

Live finance-specific insights

See more
  • HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

    Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82%Preliminary progression-free survival (PFS) was 16.3 months and preliminary overall survival (OS) rate was 88% at 9 months for the CPS 20 or higher subgroup, comparing favorably to current standard of careCompany will host a conference call at 4:15 p.m. ET today NEW YORK and VIENNA, June 04, 2024 (GLOBE NEWSWIRE) -- H

    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

    Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from approximately 40 patients treated with HB-200 in combination with pembrolizumab Two additional abstracts for HB-200 and HB-700 accepted for the ASCO 2024 Annual Meeting Company to host investor call at 8:00 a.m. ET on Thursday, April 25, 2024, to highlight path to potential registration; participant details below NEW YORK and VIENNA, Austria, April 25, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDA

    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023

    NEW YORK and VIENNA, Austria, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its third quarter 2023 financial results and business highlights on November 9, 2023. The company will not be conducting a conference call in conjunction with this financial release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight o

    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

$HOOK
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more